News|Articles|March 4, 2025
Optimizing next-generation sequencing for precision oncology trials
Author(s)Thermo Fisher Scientific
This article explores how optimizing next-generation sequencing (NGS) in oncology trials can enhance patient identification, boosts efficiency, and enables diverse recruitment.
Trending on PharmExec
1
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
2
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
3
The Evolving Relationship Between FDA and Biotech
4
Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration
5